DexCom Stock Forecast, Price & News

+11.34 (+2.53 %)
(As of 07/28/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume439,530 shs
Average Volume804,971 shs
Market Capitalization$44.48 billion
P/E Ratio90.18
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive DXCM News and Ratings via Email

Sign-up to receive the latest news and ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter.

DexCom logo

About DexCom

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

1.96 out of 5 stars

Medical Sector

329th out of 2,210 stocks

Surgical & Medical Instruments Industry

37th out of 185 stocks

Analyst Opinion: 2.4Community Rank: 3.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

DexCom (NASDAQ:DXCM) Frequently Asked Questions

Is DexCom a buy right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DexCom stock.
View analyst ratings for DexCom
or view top-rated stocks.

What stocks does MarketBeat like better than DexCom?

Wall Street analysts have given DexCom a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but DexCom wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is DexCom's next earnings date?

DexCom is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for DexCom

How can I listen to DexCom's earnings call?

DexCom will be holding an earnings conference call on Thursday, July 29th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were DexCom's earnings last quarter?

DexCom, Inc. (NASDAQ:DXCM) issued its quarterly earnings results on Thursday, April, 29th. The medical device company reported $0.33 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.31 by $0.02. The medical device company had revenue of $505 million for the quarter, compared to analysts' expectations of $482.67 million. DexCom had a net margin of 25.36% and a trailing twelve-month return on equity of 17.86%.
View DexCom's earnings history

How has DexCom's stock been impacted by COVID-19?

DexCom's stock was trading at $252.42 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, DXCM stock has increased by 82.2% and is now trading at $459.92.
View which stocks have been most impacted by COVID-19

What guidance has DexCom issued on next quarter's earnings?

DexCom issued an update on its FY 2021 earnings guidance on Thursday, May, 13th. The company provided earnings per share (EPS) guidance of - for the period. The company issued revenue guidance of $2.26 billion-$2.36 billion, compared to the consensus revenue estimate of $2.32 billion.

What price target have analysts set for DXCM?

15 equities research analysts have issued 12-month target prices for DexCom's stock. Their forecasts range from $380.00 to $525.00. On average, they anticipate DexCom's share price to reach $465.60 in the next twelve months. This suggests a possible upside of 1.2% from the stock's current price.
View analysts' price targets for DexCom
or view top-rated stocks among Wall Street analysts.

Who are DexCom's key executives?

DexCom's management team includes the following people:

What is Kevin Sayer's approval rating as DexCom's CEO?

347 employees have rated DexCom CEO Kevin Sayer on Kevin Sayer has an approval rating of 88% among DexCom's employees.

Who are some of DexCom's key competitors?

What other stocks do shareholders of DexCom own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), (CRM), ServiceNow (NOW), The Walt Disney (DIS), The Trade Desk (TTD) and Shopify (SHOP).

What is DexCom's stock symbol?

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

Who are DexCom's major shareholders?

DexCom's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include TCW Group Inc. (0.30%), Marathon Asset Management LLP (0.14%), Scout Investments Inc. (0.06%), Gradient Investments LLC (0.02%), Vancity Investment Management Ltd (0.02%) and State of Alaska Department of Revenue (0.02%). Company insiders that own DexCom stock include Andrew K Balo, Andrew K Balo, Barbara Kahn, Bridgette P Heller, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jay S Skyler, Jeffrey Moy, Jereme M Sylvain, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Paul R Flynn, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Shelly Ramasamy Selvaraj, Steven R Altman, Steven Robert Pacelli and Sumi Shrishrimal.
View institutional ownership trends for DexCom

Which institutional investors are selling DexCom stock?

DXCM stock was sold by a variety of institutional investors in the last quarter, including Compagnie Lombard Odier SCmA, Vancity Investment Management Ltd, Palisade Asset Management LLC, Patten & Patten Inc. TN, State of Alaska Department of Revenue, and New England Research & Management Inc.. Company insiders that have sold DexCom company stock in the last year include Andrew K Balo, Bridgette P Heller, Jacob Steven Leach, Jay S Skyler, Jereme M Sylvain, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Paul R Flynn, Quentin S Blackford, Richard Doubleday, Shelly Ramasamy Selvaraj, Steven R Altman, Steven Robert Pacelli, and Sumi Shrishrimal.
View insider buying and selling activity for DexCom
or view top insider-selling stocks.

Which institutional investors are buying DexCom stock?

DXCM stock was purchased by a variety of institutional investors in the last quarter, including Marathon Asset Management LLP, TCW Group Inc., CHICAGO TRUST Co NA, Gradient Investments LLC, IFM Investors Pty Ltd, Scout Investments Inc., Raymond James Trust N.A., and New Mexico Educational Retirement Board.
View insider buying and selling activity for DexCom
or or view top insider-buying stocks.

How do I buy shares of DexCom?

Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DexCom's stock price today?

One share of DXCM stock can currently be purchased for approximately $459.92.

How much money does DexCom make?

DexCom has a market capitalization of $44.48 billion and generates $1.93 billion in revenue each year. The medical device company earns $493.60 million in net income (profit) each year or $3.10 on an earnings per share basis.

How many employees does DexCom have?

DexCom employs 6,400 workers across the globe.

Does DexCom have any subsidiaries?

The following companies are subsidiares of DexCom: DexCapital LLC, DexCom (Canada) Inc., DexCom (UK) Distribution Ltd., DexCom (UK) Intermediate Holdings Ltd., DexCom (UK) Ltd., DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom Deutschland GmbH, DexCom International Ltd., DexCom Kommanditbolag, DexCom Operating Ltd., DexCom Philippines Inc, DexCom Suisse GmbH, Nintamed Handels GmbH, SweetSpot Diabetes Care Inc, The Glucose Program LLC, and TypeZero Technologies Inc.

When was DexCom founded?

DexCom was founded in 1999.

What is DexCom's official website?

The official website for DexCom is

Where are DexCom's headquarters?

DexCom is headquartered at 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121.

How can I contact DexCom?

DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-200-0200 or via email at [email protected]

This page was last updated on 7/28/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.